Antiretrovirals for HIV prevention: when should they be recommended?

References

• UNAIDS. Costing Guidelines for HIV Prevention Strategies. UNAIDS; 2000. Available from: http://data.unaids.org/publications/irc-pub05/jc412-costguidel_en.pdf
   Google Scholar
• Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369(9562):657-66
   PubMed Web of Science ®Google Scholar
• UNAIDS. UNAIDS report on the global AIDS epidemic 2013. 2013. Available from: www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf
   Google Scholar
• WHO. Consensus statement: addressing knowledge gaps in the public health approach to delivering antiretroviral therapy and care. 2008. Available from: www.iasociety.org/Web/WebContent/File/Consensus%20Statement%2030-2007-2008.pdf
   Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362(9377):22-9
   PubMed Web of Science ®Google Scholar
• Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006;368(9534):531-6
   PubMed Web of Science ®Google Scholar
• Tanser F, Barnighausen T, Grapsa E, et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013;339(6122):966-71
   PubMed Web of Science ®Google Scholar
• Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PloS One 2010;5:6
   Web of Science ®Google Scholar
• Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004;190(5):879-85
   PubMed Web of Science ®Google Scholar
• Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009;338:b164
   PubMed Web of Science ®Google Scholar
• Cohen MS, Muessig KE, Smith MK, Powers KA, Kashuba AD, Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS 2012;26(13):1585-98
   PubMed Web of Science ®Google Scholar
• Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342(13):921-9
   PubMed Web of Science ®Google Scholar
• Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368(9534):476-82
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men (MSM). N Engl J Med 2010;363(27):2587-99
   PubMed Web of Science ®Google Scholar
• Del Romero J, Castilla J, Hernando V, et al. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ 2010;340:c2205
   PubMed Web of Science ®Google Scholar
• Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010;375(9731):2092-8
   PubMed Web of Science ®Google Scholar
• Montaner JS, Wood E, Kerr T, et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr 2010;55(Suppl 1):S5-9
   PubMed Web of Science ®Google Scholar
• Granich R, Williams B, Montaner J. Fifteen million people on antiretroviral treatment by 2015: treatment as prevention. Curr Opin Hiv Aids 2013;8(1):41-9
   PubMed Web of Science ®Google Scholar
• Cowan SA, Gerstoft J, Haff J, et al. Stable incidence of HIV diagnoses among Danish men who have sex with men (MSM) despite increased engagement in unsafe sex. J Acquir Immune Defic Syndr 2012;61(1):106-11
   PubMed Web of Science ®Google Scholar
• Cohen MS. HIV treatment as prevention and “The Swiss Statement”: in for a Dime, in for a Dollar? Clin Infect Dis 2010;51(11):1323-4
   PubMed Web of Science ®Google Scholar
• Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008;198(1):59-67
   PubMed Web of Science ®Google Scholar
• UNAIDS. Treatment 2015. UNAIDS; 2012. Available from: www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2484_treatment-2015_en.pdf
   Google Scholar
• WHO. Global update on HIV treatment 2013: results, impact and opportunities.WHO; 2013. Available from: http://apps.who.int/iris/bitstream/10665/85326/1/9789241505734_eng.pdf
   Google Scholar
• Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994;154(17):1971-6
   PubMedGoogle Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331(18):1173-80
   PubMed Web of Science ®Google Scholar
• Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004;189(10):1785-92
   PubMed Web of Science ®Google Scholar
• Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007;195(7):951-9
   PubMed Web of Science ®Google Scholar
• Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005;40(1):96-101
   PubMed Web of Science ®Google Scholar
• Hernando V, del Romero J, Garcia S, et al. Reducing sexual risk behavior among steady heterosexual serodiscordant couples in a testing and counseling program. Sex Transm Dis 2009;36(10):621-8
   PubMed Web of Science ®Google Scholar
• Melo MG, Santos BR, De Cassia Lira R, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis 2008;35(11):912-15
   PubMed Web of Science ®Google Scholar
• Sullivan P, Kayitenkore K, Chomba E, et al. Reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT): misclassification of ARVT status as a methodological issue. AIDS Res Hum Retroviruses 2010;26(10):A19-19
   Web of Science ®Google Scholar
• Mayer KH, Bekker LG, Stall R, et al. Comprehensive clinical care for men who have sex with men: an integrated approach. Lancet 2012;380(9839):378-87
   PubMed Web of Science ®Google Scholar
• WHO. Guidence on couples HIV testing and councelling including antiretroviral therapy for treatment and prevention in serodiscordant couples. WHO; 2012. Available from: http://apps.who.int/iris/bitstream/10665/44646/1/9789241501972_eng.pdf?ua=1
   Google Scholar
• Wood E, Hogg RS, Yip B, et al. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS 2006;20(8):1117-23
   PubMed Web of Science ®Google Scholar
• Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000;14(4):415-21
   PubMed Web of Science ®Google Scholar
• Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997;11(10):1249-54
   PubMed Web of Science ®Google Scholar
• Lampinen TM, Critchlow CW, Kuypers JM, et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000;14(5):F69-75
   PubMed Web of Science ®Google Scholar
• Cohen MS, Holmes C, Padian N, et al. HIV Treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff 2012;31(7):1439-49
   Web of Science ®Google Scholar
• Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV transmission under highly active antiretroviral therapy. Lancet 2008;372(9652):1806-7
   PubMed Web of Science ®Google Scholar
• Vernazza PL, Hirschel B. HIV transmission hunting - the chase for low risk events. Antivir Ther 2008;13(5):641-2
   PubMed Web of Science ®Google Scholar
• Muessig KE, Smith MK, Powers KA, et al. Does ART prevent HIV transmission among MSM? AIDS 2012;26(18):2267-73
   PubMed Web of Science ®Google Scholar
• Cohen MS, Baden LR. Preexposure prophylaxis for HIV - where do we go from here? N Engl J Med 2012;367(5):459-61
   PubMed Web of Science ®Google Scholar
• Montaner JSG, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010;376(9740):532-9
   PubMed Web of Science ®Google Scholar
• Wood E, Milloy MJ, Montaner JSG. HIV treatment as prevention among injection drug users. Curr Opin HIV Aids 2012;7(2):151-6
   PubMed Web of Science ®Google Scholar
• Kirk G, Galai N, Astemborski J, et al. Decline in community viral load strongly associated with declining HIV incidence among IDU (Abstract #484). In: 18th Conference on Retroviruses and Opportunistic Infections (CROI). 27 February – 2 March 2011; Boston, MA, USA
   Google Scholar
• Birrell PJ, Gill ON, Delpech VC, et al. HIV incidence in men who have sex with men in England and Wales 2001-10: a nationwide population study. Lancet Infect Dis 2013;13(4):313-18
   PubMed Web of Science ®Google Scholar
• Phillips AN, Cambiano V, Nakagawa F, et al. Increased HIV incidence in men who have sex with men despite high levels of art-induced viral suppression: analysis of an extensively documented epidemic. PLoS One 2013;8:2
   Web of Science ®Google Scholar
• Phillips A, Cambiano V, Nakagawa F, et al. Increased HIV incidence in men who have sex with men despite high levels of ART use: analysis of an extensively documented epidemic. J Int Aids Soc 2012;15:15-15
   PubMed Web of Science ®Google Scholar
• Wand H, Yan P, Wilson D, et al. Increasing HIV transmission through male homosexual and heterosexual contact in Australia: results from an extended back-projection approach. Hiv Med 2010;11(6):395-403
   PubMed Web of Science ®Google Scholar
• van Sighem A, Jansen I, Bezemer D, et al. Increasing sexual risk behaviour among Dutch men who have sex with men: mathematical models versus prospective cohort data. AIDS 2012;26(14):1840-3
   PubMed Web of Science ®Google Scholar
• Montaner JS. Treatment as prevention: toward an AIDS-free generation. Top Antivir Med 2013;21(3):110-14
   PubMedGoogle Scholar
• Montaner JSG. Treatment as prevention-a double hat-trick. Lancet 2011;378(9787):208-9
   PubMed Web of Science ®Google Scholar
• Wirtz AL, Walker DG, Bollinger L, et al. Modelling the impact of HIV prevention and treatment for men who have sex with men on HIV epidemic trajectories in low- and middle-income countries. Int J STD Aids 2013;24(1):18-30
   PubMed Web of Science ®Google Scholar
• Vanden Berghe W, Nostlinger C, Buve A, et al. A venue-based HIV prevalence and behavioural study among men who have sex with men in Antwerp and Ghent, Flanders, Belgium, October 2009 to March 2010. Euro Surveill 2011;16:28
   PubMedGoogle Scholar
• Keebler D, Revill P, Braithwaite S, et al. Cost-effectiveness of diff erent strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Global Health 2014;2:e35-43
   PubMed Web of Science ®Google Scholar
• Hasse B, Ledergerber B, Hirschel B, et al. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2010;51(11):1314-22
   PubMed Web of Science ®Google Scholar
• Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006;3(11):e438
   PubMed Web of Science ®Google Scholar
• Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43(7):939-41
   PubMed Web of Science ®Google Scholar
• Schaecher KL. The importance of treatment adherence in HIV. Am J Manag Care 2013;19(12 Suppl):s231-7
   PubMed Web of Science ®Google Scholar
• Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008;197(Suppl 3):S272-8
   PubMed Web of Science ®Google Scholar
• Cohen MS, Smith MK, Muessig KE, et al. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet 2013;382(9903):1515-24
   PubMed Web of Science ®Google Scholar
• Smith K, Powers KA, Kashuba ADM, Cohen MS. HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV Aids 2011;6(4):315-25
   PubMed Web of Science ®Google Scholar
• Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010;84(12):6241-7
   PubMed Web of Science ®Google Scholar
• Mayer KH, Wheeler DP, Bekker LG, et al. Overcoming biological, behavioral, and structural vulnerabilities: new directions in research to decrease HIV transmission in men who have sex with men. J Acquir Immune Defic Syndr 2013;63 Suppl 2:S161-7
   PubMed Web of Science ®Google Scholar
• Soeters HM, Napravnik S, Zakharova OM, et al. Opportunities for sexual transmission of antiretroviral drug resistance among HIV-infected patients in care. AIDS 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Mark D, Amico R, Wallace M, et al. Acceptability of oral intermittent pre-exposure prophylaxis as a biomedical HIV prevention strategy: results from the South African ADAPT (HPTN 067) Preparatory Study (Abstract #TUPDC0303). In: XIX International AIDS Conference. Washington, DC, USA; 2012
   Google Scholar
• Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011;52(6):793-800
   PubMed Web of Science ®Google Scholar
• Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360(18):1815-26
   PubMed Web of Science ®Google Scholar
• Chamberland A, Sylla M, Boulassel MR, et al. Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection. Int J STD Aids 2011;22(3):146-50
   PubMed Web of Science ®Google Scholar
• Babiker AG, Emery S, Fatkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013;10(1 Suppl):S5-S36
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367(5):423-34
   PubMed Web of Science ®Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-74
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367(5):399-410
   PubMed Web of Science ®Google Scholar
• Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381(9883):2083-90
   PubMed Web of Science ®Google Scholar
• AVAC, Global. Advocacy for HIV. Ongoing and Planned PrEP Trials and Demonstration Projects 2013. Available from: www.avac.org/ht/a/GetDocumentAction/i/3113
   Google Scholar
• Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among african women. N Engl J Med 2012;367(5):411-22
   PubMed Web of Science ®Google Scholar
• Kibengo FM, Ruzagira E, Katende D, et al. Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: a Randomized, Clinical Trial. PLoS One 2013;8(9):e74314
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003) (Abstract #26LB). In: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA; 2013
   Google Scholar
• Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis 2013;13(12):1021-8
   PubMed Web of Science ®Google Scholar
• Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010;39(4):1048-63
   PubMed Web of Science ®Google Scholar
• Sullivan PS, Carballo-Dieguez A, Coates T, et al. Successes and challenges of HIV prevention in men who have sex with men. Lancet 2012;380(9839):388-99
   PubMed Web of Science ®Google Scholar
• Smith DK, Grant RM, Weidle PJ, et al. Interim Guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. (Reprinted from MMWR, vol 60, pg 65-68, 2011). JAMA 2011;305(11):1089-91
   Web of Science ®Google Scholar
• Zablotska IB, Prestage G, de Wit J, et al. The informal use of antiretrovirals for preexposure prophylaxis of HIV infection among gay men in Australia. J Acquir Immune Defic Syndr 2013;62(3):334-8
   PubMed Web of Science ®Google Scholar
• Sista ND, Abdool Karim Q, Hinson K, et al. Experience in international clinical research: the HIV Prevention Trials Network. Clin Investig (Lond) 2011;1(12):1609-18
   PubMedGoogle Scholar
• Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010;54(5):548-55
   PubMed Web of Science ®Google Scholar
• Speakman A, Rodger A, Phillips AN, et al. The ’Antiretrovirals, Sexual Transmission Risk and Attitudes’ (ASTRA) Study. Design, Methods and Participant Characteristics. PLoS ONE 2013;8(10):e77230
   PubMed Web of Science ®Google Scholar
• Cohen MS, McCauley M, Sugarman J. Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odyssey. Clin Trials 2012;9(3):340-7
   PubMed Web of Science ®Google Scholar
• Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012;380(9839):367-77
   PubMed Web of Science ®Google Scholar
• Beyrer C, Sullivan P, Sanchez J, et al. The global HIV epidemics in MSM: time to act. AIDS 2013;27(17):2665-78
   PubMed Web of Science ®Google Scholar
• Molina JM. On demand antiretroviral pre-exposure prophylaxis for HIV infection in men who have sex with men (IPERGAY). ClinicalTrials.gov. NLM Identifier: NCT01473472. National Library of Medicine, Bethesda, MD, USA; 2013. Available from: http://clinicaltrials.gov/show/NCT01473472 [Last accessed 12 February 2014]
   Google Scholar
• WHO. HIV/AIDS, Injecting drug use. WHO; 2013. Available from: www.who.int/hiv/pub/prev_care/policyprogrammingguide.pdf
   Google Scholar
• Mera RM, Rawlings MK, Pechonkina A, et al. Status of truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) in the United States: an early drug utilization analysis (Abstract #H-663a). In: 53rd interscience conference on antimicrobial agents and chemoterapy (ICAAC). Denver, CO, USA; 2013
   Google Scholar
• WHO. HIV/AIDS surveillance in Europe. European CDC; 2011. Available from: www.euro.who.int/__data/assets/pdf_file/0007/178369/HIV-AIDS-surveillance-in-Europe-2011-v4.pdf
   Google Scholar
• Eisingerich AB, Wheelock A, Gomez GB, et al. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One 2012;7(1):e28238
   PubMed Web of Science ®Google Scholar
• Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med 2013;10(9):e1001511
   PubMed Web of Science ®Google Scholar
• Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012;4(151):151ra125
   PubMed Web of Science ®Google Scholar
• Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV Aids 2013;8(6):565-71
   PubMed Web of Science ®Google Scholar
• Celum C, Baeten JM. Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther 2012;17(8):1483-93
   PubMed Web of Science ®Google Scholar
• Cremin I, Alsallaq R, Dybul M, et al. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 2013;27(3):447-58
   PubMed Web of Science ®Google Scholar
• Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004;292(2):224-36
   PubMed Web of Science ®Google Scholar
• Iwuji CC, Orne-Gliemann J, Tanser F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials 2013;14:230
   PubMed Web of Science ®Google Scholar
• Griffith S, Moore A. Population effects of antiretroviral therapy to reduce HIV transmission (PopART). ClinicalTrials.gov. NLM Identifier: NCT01900977. National Library of Medicine, Bethesda, MD, USA; 2013. Available from: http://clinicaltrials.gov/show/NCT01900977 [Last accessed 12 February 2014]
   Google Scholar
• Kurth A, Lizcano J. Testing and linkage to care for injecting drug users in Kenya (TLC-IDU Kenya). ClinicalTrials.gov. NLM Identifier: NCT01557998. National Library of Medicine, Bethesda, MD, USA; 2012. Available from: http://clinicaltrials.gov/show/NCT01557998 [Last accessed 12 February 2014]
   Google Scholar
• Genz A, Lucas L. Technology-enhanced peer navigation to improve IDUs’ engagement in HIV Care (mP2P). ClinicalTrials.gov. NLM Identifier: NCT01941108. National Library of Medicine, Bethesda, MD, USA; 2013. Available from: http://clinicaltrials.gov/show/NCT01941108 [Last accessed 12 February 2014]
   Google Scholar